Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule

References

• Slack MPE, Cripps AW, Grimwood K, Mackenzie GA, Ulanova M. Invasive haemophilus influenzae infections after 3 decades of hib protein conjugate vaccine use. Clin Microbiol Rev. 2021;34(3):e0002821. doi:10.1128/CMR.00028-21.
   PubMed Web of Science ®Google Scholar
• Slack M, Esposito S, Haas H, Mihalyi A, Nissen M, Mukherjee P, Harrington L. Haemophilus influenzae type b disease in the era of conjugate vaccines: critical factors for successful eradication. Expert Rev Vaccines. 2020;19(10):903–11. doi:10.1080/14760584.2020.1825948.
   PubMed Web of Science ®Google Scholar
• Wang S, Tafalla M, Hanssens L, Dolhain J. A review of haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines. 2017;16(11):1095–105. doi:10.1080/14760584.2017.1383157.
   PubMed Web of Science ®Google Scholar
• Anderson P. The protective level of serum antibodies to the capsular polysaccharide of haemophilus influenzae type b. J Infect Dis. 1984;149(6):1034–5. doi:10.1093/infdis/149.6.1034.
   PubMed Web of Science ®Google Scholar
• Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of haemophilus influenzae type b. J Infect Dis. 1983;147(6):1100. doi:10.1093/infdis/147.6.1100.
   PubMed Web of Science ®Google Scholar
• Barbour ML. Conjugate vaccines and the carriage of haemophilus influenzae type b. Emerg Infect Dis. 1996;2(3):176–82. doi:10.3201/eid0203.960303.
   PubMed Web of Science ®Google Scholar
• Peltola H, Käyhty H, Sivonen A, Mäkelä H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics. 1977;60(5):730–7. doi:10.1542/peds.60.5.730.
   PubMed Web of Science ®Google Scholar
• Fernandez J, Levine OS, Sanchez J, Balter S, LaClaire L, Feris J, Romero‐Steiner S. Prevention of haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis. 2000;182(5):1553–6. doi:10.1086/315870.
   PubMed Web of Science ®Google Scholar
• Lee YC, Kelly DF, Yu LM, Slack MPE, Booy R, Heath PT, Siegrist C-A, Moxon RE, Pollard AJ. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis. 2008;46(2):186–92. doi:10.1086/524668.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European public assessment report - Hexyon. 2023 Jun 23 [Accessed 2023 Jul 23]. https://www.ema.europa.eu/en/medicines/human/EPAR/hexyon.
   Google Scholar
• European Medicines Agency. European public assessment report - Infanrix Hexa. 2023 May 24 [Accessed 2023 Jul 23]. https://www.ema.europa.eu/en/medicines/human/EPAR/infanrix-hexa.
   Google Scholar
• European Medicines Agency. European public assessment report - Vaxelis. 2023 Feb 20 [Accessed 2023 Jul 23]. https://www.ema.europa.eu/en/medicines/human/EPAR/vaxelis.
   Google Scholar
• Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F. et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36(2):209–15. doi:10.1097/inf.0000000000001406.
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S. et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months. Vaccine. 2016;34(33):3810–6. doi:10.1016/j.vaccine.2016.05.054.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Silfverdal SA, Jordanov E, Feroldi E. A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5- and 11- to 12-month schedule. Pediatr Infect Dis J. 2017;36(1):87–93. doi:10.1097/INF.0000000000001358.
   PubMed Web of Science ®Google Scholar
• Agbarakwe AE, Griffiths H, Begg N, Chapel HM. Avidity of specific IgG antibodies elicited by immunisation against haemophilus influenzae type b. J Clin Pathol. 1995;48(3):206–9. doi:10.1136/jcp.48.3.206.
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Granoff DM, Murphy TV, Osterholm MT, McHugh JE, Anderson R, Esbenshade J, Blatter M, Reisinger KS, Keyserling H. Avidity and bactericidal activity of antibody elicited by different haemophilus influenzae type b conjugate vaccines. The vaccine study group. JAMA. 1992;267(11):1489–94. doi:10.1001/jama.1992.03480110065035.
   PubMed Web of Science ®Google Scholar
• Mäkelä PH. Conjugate vaccines–a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health. 2003;34:249–53.
   PubMedGoogle Scholar
• European Medicines Agency. European public assessment report - Bexsero. 2023 Jul 19 [Accessed 2023 Jul 23]. https://www.ema.europa.eu/en/medicines/human/EPAR/bexsero.
   Google Scholar
• Borrow R, Findlow J. Prevention of meningococcal serogroup C disease by NeisVac-C™. Expert Rev Vaccines. 2009;8(3):265–79. doi:10.1586/14760584.8.3.265.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European public assessment report - Nimenrix. 2023 Jul 17 [Accessed 2023 Jul 23]. https://www.ema.europa.eu/en/medicines/human/EPAR/nimenrix.
   Google Scholar
• Lee JH, Sutton HJ, Cottrell CA, Phung I, Ozorowski G, Sewall LM, Nedellec R, Nakao C, Silva M, Richey ST. et al. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature. 2022;609(7929):998–1004. doi:10.1038/s41586-022-05216-9.
   PubMed Web of Science ®Google Scholar
• Rajan M, Marchevsky N, Sinclair G, O’Brien K, Jefferies K, Owino N, Hallis B, Goldblatt D, Matheson M, Cuthbertson H. et al. A randomized trial assessing the immunogenicity and reactogenicity of two hexavalent infant vaccines concomitantly administered with group B meningococcal vaccine. Pediatr Infect Dis J. 2023;42(1):66–73. doi:10.1097/INF.0000000000003753.
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-Del-Río M. et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2006;25(8):713–20. doi:10.1097/01.inf.0000227725.61495.c4.
   PubMed Web of Science ®Google Scholar
• Borrow R, Dagan R, Zepp F, Hallander H, Poolman J. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines. 2011;10(11):1621–31. doi:10.1586/erv.11.142.
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010;28(34):5513–23. doi:10.1016/j.vaccine.2010.06.026.
   PubMed Web of Science ®Google Scholar
• Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton PM, Panzer F, Rose T. et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J. 2009;28(3):177–81. doi:10.1097/INF.0b013e31818c0161.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Thollot F, Garcia-Corbeira P, Damaso S, Han H-H, Bouckenooghe A. et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix™ co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine. 2010;28(32):5272–9. doi:10.1016/j.vaccine.2010.05.057.
   PubMed Web of Science ®Google Scholar
• Gillard P, Tamura T, Kuroki H, Morikawa Y, Moerman L, Parra J, Kitamura Y, Mihara K, Okamasa A. Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study. Hum Vaccin Immunother. 2019;15(4):800–8. doi:10.1080/21645515.2018.1564441.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, De Gregorio E, Costantino P. On the mechanisms of conjugate vaccines. Proc Natl Acad Sci USA. 2019;116(1):14–16. doi:10.1073/pnas.1819612116.
   PubMed Web of Science ®Google Scholar
• Monge S, Hahné SJ, de Melker HE, Sanders EA, van der Ende A, Knol MJ. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study. Lancet Infect Dis. 2018;18(7):749–57. doi:10.1016/s1473-3099(18)30166-x.
   PubMed Web of Science ®Google Scholar
• Ricci S, Canessa C, Lodi L, Giovannini M, Lippi F, Moriondo M, Nieddu F, Azzari C. Invasive haemophilus influenzae type b disease in the post hexavalent era: ten years of molecular surveillance in tuscany. Pediatr Infect Dis J. 2020;39(4):294–7. doi:10.1097/inf.0000000000002588.
   PubMed Web of Science ®Google Scholar
• Steens A, Stanoeva KR, Knol MJ, Mariman R, de Melker HE, van Sorge NM. Increase in invasive disease caused by haemophilus influenzae b, the Netherlands, 2020 to 2021. Euro Surveill. 2021;26(42). doi: 10.2807/1560-7917.Es.2021.26.42.2100956.
   PubMedGoogle Scholar